News
Expert CA Rudramurthy BV suggests a bullish stance. He recommends buying on dips, especially in pharma stocks like Glenmark, ...
Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...
The stock’s current performance reflects a positive investor response, with Biocon demonstrating promising financial results ...
Bangalore: Biocon has announced the appointment of Ekta Agarwal as the Interim Company Secretary and Compliance Officer ...
The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab.
Syngene International, in collaboration with the Research and Innovation Circle of Hyderabad (RICH) and Biocon Foundation, has announced the launch of the third cohort of its flagship women-in-STEM ...
On July 9, even when the 90-day pause of Liberation Day ended, Nifty Pharma jumped by over 101 points before correcting.
Biocon share price gained 2.5 per cent after reports suggested that the company is planning to file for generic versions of ...
8d
GlobalData on MSNBiocon’s Denosumab biosimilars gain EU marketing authorisationClinical trials have demonstrated that both biosimilars match the reference product's quality, safety and efficacy standards.
The pharma sector will be in focus on July 9, after Donald Trump said that he would make an announcement on pharmaceuticals ...
Biocon Biologics receives marketing authorizations for Vevzuo and Evfraxy biosimilars for bone-related diseases in the UK.
Biocon Biologics Ltd received UK approval for Vevzuo and Evfraxy, biosimilars of Denosumab. Vevzuo is approved for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results